 WESTPORT, Conn., Aug. 05, 2021 GLOBE NEWSWIRE -- Portage Biotech Inc., NASDAQ: PRTG Portage or the Company a clinical-stage immuno-oncology company focused on the development of therapies targeting cancer treatment resistance, today announced that the first patient has been dosed in the Oxford-led IMP-MEL study, a Phase 12, open-label, dose-escalation and randomized expansion clinical trial assessing the safety, tolerability and efficacy of PORT-2, a liposome formulation of the invariant natural killer T-cell iNKT agonist IMM60 developed for the treatment of solid tumors. 